Trial Profile
The effect of Ranibizumab (Lucentis) combined with grid laser compared with laser alone on vision in patients with recalcitrant, diabetic macular oedema
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Jun 2016
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Acronyms DMO Rescue Trial
- Sponsors Novartis
- 08 Jun 2016 Status changed from recruiting to completed.
- 24 Jan 2011 New trial record